Cargando…

Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia

BACKGROUND: The role of branched-chain amino acids (BCAA) in improving muscle mass in cirrhosis is presently debatable. AIMS: To evaluate the role of BCAA in improving muscle mass in a double-blind randomized placebo-controlled trial in patients with cirrhosis having sarcopenia. METHODS: Consecutive...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohta, Srikant, Anand, Abhinav, Sharma, Sanchit, Qamar, Sumaira, Agarwal, Samagra, Gunjan, Deepak, Singh, Namrata, Madhusudhan, Kumble Seetarama, Pandey, Ravindra Mohan, Saraya, Anoop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037580/
https://www.ncbi.nlm.nih.gov/pubmed/35469091
http://dx.doi.org/10.1007/s12072-022-10334-7
_version_ 1784693751420026880
author Mohta, Srikant
Anand, Abhinav
Sharma, Sanchit
Qamar, Sumaira
Agarwal, Samagra
Gunjan, Deepak
Singh, Namrata
Madhusudhan, Kumble Seetarama
Pandey, Ravindra Mohan
Saraya, Anoop
author_facet Mohta, Srikant
Anand, Abhinav
Sharma, Sanchit
Qamar, Sumaira
Agarwal, Samagra
Gunjan, Deepak
Singh, Namrata
Madhusudhan, Kumble Seetarama
Pandey, Ravindra Mohan
Saraya, Anoop
author_sort Mohta, Srikant
collection PubMed
description BACKGROUND: The role of branched-chain amino acids (BCAA) in improving muscle mass in cirrhosis is presently debatable. AIMS: To evaluate the role of BCAA in improving muscle mass in a double-blind randomized placebo-controlled trial in patients with cirrhosis having sarcopenia. METHODS: Consecutive patients with cirrhosis with Child–Pugh score < 10 and sarcopenia were randomized to receive either 12 g/day of BCAA orally or a placebo (1:1) for 6 months in addition to a home-based exercise program (30 min/day), dietary counselling and standard medical therapy. Sarcopenia was defined according to gender-specific axial skeletal muscle index (SMI) cut-offs. The primary endpoint was a change in muscle mass based on CT scan (SMI) after 6 months of supplementation. RESULTS: Sixty patients [mean age 41.6 ± 9.9 years; males (66.6%) of predominantly viral (40%) and alcohol-related (31.7%) cirrhosis] were randomized. Baseline clinical and demographic characters were similar except MELD score (10.2 ± 2.8 vs. 12.2 ± 3.5, p = 0.02) and calorie intake (1838.1 kcal ± 631.5 vs. 2217.5 kcal ± 707.3, p = 0.03), both being higher in the placebo arm. After adjusting for both baseline confounders, baseline SMI and protein intake, the change in SMI at 6 months was similar in both groups [mean adjusted difference (MAD) + 0.84, CI − 2.9; + 1.2, p = 0.42] by intention-to-treat analysis. The secondary outcomes including change in handgrip strength (p = 0.65), 6-m gait speed (p = 0.20), 6-min walk distance (p = 0.39) were similar in both arms. Four patients had minor adverse events in each arm. CONCLUSION: Addition of BCAA to exercise, dietary counselling and standard medical therapy did not improve muscle mass in patients with cirrhosis having sarcopenia. (CTRI/2019/05/019269). TRIAL REGISTRATION NUMBER: CTRI/2019/05/019269 (Clinical Trials Registry of India). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-022-10334-7.
format Online
Article
Text
id pubmed-9037580
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-90375802022-04-26 Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia Mohta, Srikant Anand, Abhinav Sharma, Sanchit Qamar, Sumaira Agarwal, Samagra Gunjan, Deepak Singh, Namrata Madhusudhan, Kumble Seetarama Pandey, Ravindra Mohan Saraya, Anoop Hepatol Int Original Article BACKGROUND: The role of branched-chain amino acids (BCAA) in improving muscle mass in cirrhosis is presently debatable. AIMS: To evaluate the role of BCAA in improving muscle mass in a double-blind randomized placebo-controlled trial in patients with cirrhosis having sarcopenia. METHODS: Consecutive patients with cirrhosis with Child–Pugh score < 10 and sarcopenia were randomized to receive either 12 g/day of BCAA orally or a placebo (1:1) for 6 months in addition to a home-based exercise program (30 min/day), dietary counselling and standard medical therapy. Sarcopenia was defined according to gender-specific axial skeletal muscle index (SMI) cut-offs. The primary endpoint was a change in muscle mass based on CT scan (SMI) after 6 months of supplementation. RESULTS: Sixty patients [mean age 41.6 ± 9.9 years; males (66.6%) of predominantly viral (40%) and alcohol-related (31.7%) cirrhosis] were randomized. Baseline clinical and demographic characters were similar except MELD score (10.2 ± 2.8 vs. 12.2 ± 3.5, p = 0.02) and calorie intake (1838.1 kcal ± 631.5 vs. 2217.5 kcal ± 707.3, p = 0.03), both being higher in the placebo arm. After adjusting for both baseline confounders, baseline SMI and protein intake, the change in SMI at 6 months was similar in both groups [mean adjusted difference (MAD) + 0.84, CI − 2.9; + 1.2, p = 0.42] by intention-to-treat analysis. The secondary outcomes including change in handgrip strength (p = 0.65), 6-m gait speed (p = 0.20), 6-min walk distance (p = 0.39) were similar in both arms. Four patients had minor adverse events in each arm. CONCLUSION: Addition of BCAA to exercise, dietary counselling and standard medical therapy did not improve muscle mass in patients with cirrhosis having sarcopenia. (CTRI/2019/05/019269). TRIAL REGISTRATION NUMBER: CTRI/2019/05/019269 (Clinical Trials Registry of India). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-022-10334-7. Springer India 2022-04-25 /pmc/articles/PMC9037580/ /pubmed/35469091 http://dx.doi.org/10.1007/s12072-022-10334-7 Text en © Asian Pacific Association for the Study of the Liver 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Mohta, Srikant
Anand, Abhinav
Sharma, Sanchit
Qamar, Sumaira
Agarwal, Samagra
Gunjan, Deepak
Singh, Namrata
Madhusudhan, Kumble Seetarama
Pandey, Ravindra Mohan
Saraya, Anoop
Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia
title Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia
title_full Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia
title_fullStr Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia
title_full_unstemmed Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia
title_short Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia
title_sort randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037580/
https://www.ncbi.nlm.nih.gov/pubmed/35469091
http://dx.doi.org/10.1007/s12072-022-10334-7
work_keys_str_mv AT mohtasrikant randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT anandabhinav randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT sharmasanchit randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT qamarsumaira randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT agarwalsamagra randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT gunjandeepak randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT singhnamrata randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT madhusudhankumbleseetarama randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT pandeyravindramohan randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia
AT sarayaanoop randomisedclinicaltrialeffectofaddingbranchedchainaminoacidstoexerciseandstandardofcareonmusclemassincirrhoticpatientswithsarcopenia